Loading
Life sciences · Observational Study
ClinicalTrials.gov · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06329414). This is a study registration, not published results. Lead sponsor: University of Utah. Recruitment status: WITHDRAWN. Study type: OBSERVATIONAL. Conditions: Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression. Primary outcome measures: Feasibility of TMS treatment for MDD, per participant retention rates. , 10 weeks; Safety and tolerability, to be evaluated by side effects and adverse events over the course of treatment. , 10 weeks. Brief summary: The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment.